FUB-AMB (also known as AMB-FUBINACA and MMB-FUBINACA) is an indazole-based synthetic cannabinoid that is a potent agonist for the cannabinoid CB1 and CB2 receptors. It was originally developed by Pfizer which described the compound in a patent in 2009, but was later abandoned and never tested on humans.
Cas No: 1715016-76-4
Formula: C21H22FN3O3
IUPAC:
Appearance:
Purity: 99.99%